PharmaEssentia Corporation
6446
Rank in Stocks
#1418
PharmaEssentia Corporation is a biopharmaceutical firm dedicated to developing... PharmaEssentia Corporation is a biopharmaceutical firm dedicated to developing therapies for human ailments, serving both the Taiwanese and international markets. Its product portfolio prominently features Ropeginterferon alfa-2b, indicated for the management of various hematological conditions including chronic myelogenous leukemia, T-Cell leukemia, early myelofibrosis, polycythemia vera, and essential thrombocythemia. Beyond this, the company's pipeline includes TCRT, anti PD-1, PEG-cytokine X,Y, and novel checkpoint antibodies, all under development for solid tumors. A specific combination, P1101 + anti PD-1, is being explored for hepatocellular carcinoma, while PEG-GCSF addresses neutropenia. Fundamentally, its comprehensive research and development initiatives span key therapeutic areas such as hematology, infectious diseases, and oncology. Established in 1990, PharmaEssentia Corporation maintains its headquarters in Taipei, Taiwan.
Share Price
$37.84
Market Cap
$15.65B
Change (1 day)
-4.42%
Change (1 year)
149.23%
Country
TW
Trade PharmaEssentia Corporation (6446)
Category
Healthcare
Earnings for PharmaEssentia Corporation (6446)
Earnings in Jun 2026 TTM: $284.95M
According to PharmaEssentia Corporation latest financial reports the company's current earnings are $284.95M. In 2023 the company made an earning of $-32.16M, an increase over its 2022 earnings that were of $-60.07M. The earnings displayed on this page are the earnings before interest and taxes or simply EBIT.
Earnings history for PharmaEssentia Corporation from 2010 to 2026
Earnings at the end of each year
| Year | Earnings | Change |
|---|---|---|
| 2026 (TTM) | $284.95M | 212.31% |
| 2024 | $91.24M | -383.66% |
| 2023 | $-32.16M | -46.45% |
| 2022 | $-60.07M | -40.77% |
| 2021 | $-101.42M | 46.26% |
| 2020 | $-69.34M | 146.30% |
| 2019 | $-28.15M | -17.15% |
| 2018 | $-33.98M | 15.54% |
| 2017 | $-29.41M | 12.91% |
| 2016 | $-26.05M | 0.49% |
| 2015 | $-25.92M | -3.64% |
| 2014 | $-26.90M | 35.45% |
| 2013 | $-19.86M | 125.31% |
| 2012 | $-8.81M | 31.09% |
| 2011 | $-6.72M | 17.15% |
| 2010 | $-5.74M | 0.00% |
Earnings for similar companies or competitors
| Company | Earnings | Earnings Difference | Country |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| $1.76B | 519.26% |
IN
|
